ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer
Rowan Miller(Queen Mary University of London), Lucy Yates(University of Cambridge), Alexandra Léary(Institut Gustave Roussy), Sohrab P. Shah(Memorial Sloan Kettering Cancer Center), Jos Jonkers(The Netherlands Cancer Institute), Xavier Matías‐Guiu(Universitat de Lleida), Serena Nik‐Zainal(University of Cambridge), Violeta Serra(Vall d'Hebron Institute of Oncology), Isabelle Ray‐Coquard(Centre Léon Bérard), Dale W. Garsed(Peter MacCallum Cancer Centre), Jonathan A. Ledermann(London Cancer), Elizabeth M. Swisher(University of Washington), Clare L. Scott(Walter and Eliza Hall Institute of Medical Research), David K. Chang(University of Glasgow), Christopher J. Lord(Institute of Cancer Research), David D.L. Bowtell(The University of Melbourne)
Cited by 478
Related Papers
Signatures of mutational processes in human cancer
|Nature|2013|10.1k
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
|New England Journal of Medicine|2016|2.5k
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
|New England Journal of Medicine|2015|2.2k